Jun 15 2020
Webinar Description:
The rapid development of immuno-oncology (IO) therapies has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer. Among these, checkpoint inhibitors represent a promising therapeutic approach for a wide range of cancers. For instance, PD-1/PD-L1-targeted monoclonal antibodies (mAbs) are now the standard of care for 16 different types of cancer and tissue-agnostic indications. Among them, Pembrolizumab is the most prescribed.
Unfortunately, the response rate for PD-1 monotherapies is insufficient and synergetic strategies are the next logical step to overcome anti PD-1 resistance and address this unmet need. As of end of 2019, up to 2975 combination trials of anti PD1/PD-L1 agents were under way in combination with 295 targets. This trend is led by combinations of chemotherapies with PD-1 and angiogenesis inhibitors with PD-1. This high number of clinical trials highlights a high potential utility from this combination strategy. There is a real need for a suitable and efficient in vivo model able to screen a wide variety of drug combinations before clinical trials – given the high time and cost of each combination.
During the webinar Dr Yan Wang will discuss:
– Benefits of setting up an early in vivo efficacy evaluation to optimize probability of success for synergistic Immuno-oncology drug candidate
– Learn about chicken embryo model
– Understand the interest of xenograft on chicken embryo model
– Chicken embryo in vivo model for early efficacy and toxicity evaluation of Immuno-oncology drug candidates
– Understand pros and cons of chicken embryo model vs mouse model in Immuno-oncology
– Case studies
Learning Objectives:
– Benefits of setting up an early in vivo efficacy evaluation to optimize probability of success for synergistic Immuno-oncology drug candidate
– Chicken embryo in vivo model for early efficacy and toxicity evaluation of Immuno-oncology drug candidates
– Understand pros and cons of chicken embryo model vs mouse model in immuno-oncology
DOWNLOAD OUR WEBINAR:
Nov 28-30
2023
Come and join us at NLS DAYS, Nov 28-30 2023 in Copenhagen, Sweden
Join INOVOTION at the NLS Days’ 10th anniversary in Copenhagen. This is the premier Nordic event for partnering in Life Sciences. Come and meet INOVOTION on the MabDesign/Choose France stand (A37-38-39-40-41). This is huge opportunity to learn […]
Nov 22
2023
ORGA-SOFT-OVO project formally accepted for funding
INOVOTION and its partners Cell&Soft, Hospices Civils de Lyon – HCL, and CRCL Centre de Recherche en Cancérologie de Lyon proudly announce that its ambitious ORGA-SOFT-OVO project has been formally accepted for funding. This is […]
Nov 6-8
2023
Come and join us at BIO-EUROPE, Nov 6-8 2023 in Munich, Germany
Join INOVOTION at this exciting event, to learn about our unique model for in vivo cancer drug evaluation. Connect with the right partners at Europe’s largest partnering event. Sales Director Arnaud Peyronnier and CEO/CSO Jean Viallet will […]
